New eczema drug shows promise in Mid-Stage trial
Disease control
Ongoing
This study tests whether ATI-045 can safely reduce eczema symptoms like redness, itching, and skin patches in people with moderate-to-severe disease. About 110 adults who haven't had success with topical treatments will receive either the drug or a placebo. The main goal is to se…
Phase: PHASE2 • Sponsor: Aclaris Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC